Why stronger radiation safety measures are essential for the modern workforce. A perspective from EAPCI women and women as one

Gill Louise Buchanan; Rebecca Ortega; Alaide Chieffo; Roxana Mehran; Martine Gilard; Marie Claude Morice

doi:10.4244/EIJV16I1A5

Why stronger radiation safety measures are essential for the modern workforce. A perspective from EAPCI women and women as one

Gill Louise Buchanan, Rebecca Ortega, Alaide Chieffo, Roxana Mehran, Martine Gilard, Marie Claude Morice

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	24-25
Number of pages	2
Journal	EuroIntervention
Volume	16
Issue number	1
DOIs	https://doi.org/10.4244/EIJV16I1A5
State	Published - May 2020

Access to Document

10.4244/EIJV16I1A5

Cite this

@article{5704f5f1611348279993fc3043c5a971,

title = "Why stronger radiation safety measures are essential for the modern workforce. A perspective from EAPCI women and women as one",

author = "Buchanan, {Gill Louise} and Rebecca Ortega and Alaide Chieffo and Roxana Mehran and Martine Gilard and Morice, {Marie Claude}",

note = "Funding Information: A. Chieffo declares that she has received speaker/consultant fees from Abbott, Abiomed, Biosensors, Cardinal Health, and Magenta. R. Mehran declares that she has received grants, personal fees and other from Abbott Laboratories, grants from AstraZeneca, Bayer, Beth Israel Deaconess, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, and OrbusNeich, grants and other from Bristol-Myers Squibb, other from Abiomed, and The Medicines Company, personal fees from Boston Scientific, Janssen Scientific Affairs, Medscape/WebMD, Roivant Services, Sanofi, and Siemens Medical Solutions, nonfinancial support and other from Idorsia Pharmaceuticals Ltd., and Regeneron Pharmaceuticals, other from Spectranetics/ Philips/Volcano Corp, personal fees from Medtelligence (Janssen Scientific Affairs), other from Watermark Research Partners, Claret Medical, and Elixir Medical, and personal fees from ACC and AMA, outside the submitted work. M.-C. Morice declares that she is the CEO and a shareholder of CERC, a CRO based in Paris. The other authors have no conflicts of interest to declare.",

year = "2020",

month = may,

doi = "10.4244/EIJV16I1A5",

language = "English",

volume = "16",

pages = "24--25",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "EuroPCR",

number = "1",

}

TY - JOUR

T1 - Why stronger radiation safety measures are essential for the modern workforce. A perspective from EAPCI women and women as one

AU - Buchanan, Gill Louise

AU - Ortega, Rebecca

AU - Chieffo, Alaide

AU - Mehran, Roxana

AU - Gilard, Martine

AU - Morice, Marie Claude

N1 - Funding Information: A. Chieffo declares that she has received speaker/consultant fees from Abbott, Abiomed, Biosensors, Cardinal Health, and Magenta. R. Mehran declares that she has received grants, personal fees and other from Abbott Laboratories, grants from AstraZeneca, Bayer, Beth Israel Deaconess, CERC, Chiesi, Concept Medical, CSL Behring, DSI, Medtronic, Novartis Pharmaceuticals, and OrbusNeich, grants and other from Bristol-Myers Squibb, other from Abiomed, and The Medicines Company, personal fees from Boston Scientific, Janssen Scientific Affairs, Medscape/WebMD, Roivant Services, Sanofi, and Siemens Medical Solutions, nonfinancial support and other from Idorsia Pharmaceuticals Ltd., and Regeneron Pharmaceuticals, other from Spectranetics/ Philips/Volcano Corp, personal fees from Medtelligence (Janssen Scientific Affairs), other from Watermark Research Partners, Claret Medical, and Elixir Medical, and personal fees from ACC and AMA, outside the submitted work. M.-C. Morice declares that she is the CEO and a shareholder of CERC, a CRO based in Paris. The other authors have no conflicts of interest to declare.

PY - 2020/5

Y1 - 2020/5

UR - http://www.scopus.com/inward/record.url?scp=85085155836&partnerID=8YFLogxK

U2 - 10.4244/EIJV16I1A5

DO - 10.4244/EIJV16I1A5

M3 - Review article

C2 - 32439628

AN - SCOPUS:85085155836

SN - 1774-024X

VL - 16

SP - 24

EP - 25

JO - EuroIntervention

JF - EuroIntervention

IS - 1

ER -